FDA Approves First mRNA Flu Vaccine: What Older Adults Need to Know for the 2026-27 Flu Season

The U.S. Food and Drug Administration (FDA) has approved mFLUSIVA, the first mRNA-based influenza vaccine, for adults aged 50 and older — just in time for the 2026–2027 flu season. Manufactured by Moderna, the vaccine uses the same messenger RNA technology that powered the COVID-19 vaccines and marks a major turning point in how seasonal flu shots are made and updated.

For older adults — the group at highest risk of serious flu complications — the approval adds a powerful new option to the seasonal vaccination toolkit. Here is what you need to know about the new shot, what the science shows, and how it could change flu prevention for years to come.

What is mFLUSIVA?

mFLUSIVA (mRNA-1010) is an mRNA vaccine designed to teach the body to produce influenza antigens and trigger a protective immune response. Unlike traditional flu shots, which are largely egg-based and contain inactivated viral proteins, mRNA vaccines carry genetic instructions that prompt cells to build a harmless piece of the virus so the immune system can recognize and fight it.

The FDA granted approval for adults aged 50 to 64 based on a phase 3 clinical trial involving more than 40,000 adults in 11 countries. The results, published in the New England Journal of Medicine, showed the mRNA shot was 26% more effective at preventing serious illness than a licensed standard-dose flu vaccine.

The agency also granted accelerated approval for adults aged 65 and older, based on a separate trial of nearly 3,000 older adults in the United States. Moderna reported that mFLUSIVA generated stronger antibody responses than the leading high-dose flu vaccine in this age group. The company has agreed to run an additional confirmatory study and submit more data in adults 65 and older.

Why this matters for the 2026–27 flu season

Influenza remains a serious public health threat. Last winter, the United States experienced a moderately severe flu season driven largely by the H3N2 variant. Australia — often a preview of what the Northern Hemisphere can expect — recorded its deadliest flu season of the 21st century last year, with nearly 500,000 cases and 1,700 deaths, fuelled by a variant nicknamed “Super K.”

This year’s Australian season has been moderate to lower than average, a cautiously encouraging sign. Still, experts stress it is too early to predict how severe the coming Northern Hemisphere season will be, and influenza activity typically begins to climb in the late autumn.

Key advantages of mRNA flu vaccines

• Better protection: In clinical trials, mFLUSIVA outperformed a standard-dose flu shot in adults 50 to 64, reducing serious illness by 26%.
• Faster updates: Because mRNA vaccines do not rely on egg-based production, they can be redesigned quickly when circulating flu strains mutate — addressing the perennial problem of vaccine-virus mismatch.
• Stronger immune response in seniors: Early data suggest stronger antibody responses than high-dose vaccines in adults 65 and older, with confirmatory studies underway.
• Proven platform: The same technology has already been used safely in billions of COVID-19 vaccine doses worldwide.

What experts are saying

“I view the FDA approval of mFLUSIVA as an important addition to our influenza prevention toolkit, particularly because adults over 50 begin to experience a progressively higher risk of serious complications from influenza,” said Dr. Dung Trinh, an internist at MemorialCare Medical Group and chief medical officer of the Healthy Brain Clinic in Irvine, California.

“This is also a significant scientific milestone because it is the first mRNA-based seasonal influenza vaccine approved in the United States, showing that mRNA technology can be applied beyond COVID-19,” Trinh added.

Dr. David Cutler, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, described himself as “cautiously favorable,” noting that mRNA vaccines can be redesigned as flu viruses mutate. “That could become increasingly valuable for influenza, where vaccine-virus mismatch is a perennial problem,” he said.

How does mFLUSIVA compare with current flu shots?

mFLUSIVA will not replace existing flu vaccines. Traditional shots manufactured by Sanofi, GSK, CSL Seqirus and AstraZeneca will remain available — none of them mRNA-based. Instead, the new vaccine adds an evidence-based choice, particularly for people at higher risk. It is also currently under regulatory review in Europe, Canada and Australia, which could expand global access in coming seasons.

When and where can older adults get it?

The vaccine is expected to be available in the United States ahead of the 2026–2027 flu season, which typically peaks between December and February. Public health authorities recommend that adults aged 50 and older get vaccinated before flu activity begins to spread widely — ideally in September or October. As with other flu vaccines, the mRNA shot is administered as a single dose.

Frequently asked questions

Is the mRNA flu vaccine safe?

Yes. The vaccine was evaluated in large clinical trials involving tens of thousands of participants, and the mRNA platform has an extensive safety record from COVID-19 vaccination campaigns. The FDA reviewed the data before granting approval and accelerated approval.

Who is eligible for mFLUSIVA?

The vaccine is approved for adults aged 50 and older. It received full approval for ages 50 to 64 and accelerated approval for ages 65 and older, with additional confirmatory data expected.

How effective is the mRNA flu vaccine compared with standard flu shots?

In a phase 3 trial of more than 40,000 adults, mFLUSIVA was 26% more effective than a licensed standard-dose flu vaccine at preventing serious illness in adults aged 50 to 64. In adults 65 and older, it produced stronger antibody responses than a high-dose comparator vaccine, with confirmatory studies ongoing.

Can the mRNA flu vaccine be updated quickly for new strains?

Yes — and that is one of its biggest advantages. Because mRNA vaccines do not depend on egg-based manufacturing, they can be adapted more quickly when circulating flu strains change, potentially reducing vaccine-virus mismatch.

Should I still get a flu shot if I had one last year?

Yes. Flu viruses change from season to season, and immunity from vaccination wanes over time. Annual vaccination remains the best protection against seasonal influenza, especially for older adults and people with chronic health conditions.

The bottom line

The approval of mFLUSIVA is a genuine milestone in influenza prevention — the first time mRNA technology has been cleared for a seasonal flu vaccine. For adults 50 and older, it offers a new, potentially more effective option just ahead of the 2026–2027 flu season. As more data emerge in adults 65 and older and regulators in other countries weigh in, mRNA flu vaccines could become a cornerstone of annual respiratory protection — one that can keep pace with a virus that never stops changing.

This article is for informational purposes only and is not a substitute for professional medical advice. Talk to your doctor or pharmacist about which flu vaccine is right for you.